Mouse Anti-OIT3 Recombinant Antibody (CBYCL-619) (CBMAB-L0520-YC)

Wen, J., Yang, S., Yan, G., Lei, J., Liu, X., Zhang, N., ... & Li, Y. (2023). Increased OIT3 in macrophages promotes PD-L1 expression and hepatocellular carcinogenesis via NF-κB signaling. Experimental Cell Research, 428(2), 113651.

Li, Z. W., Ruan, B., Yang, P. J., Liu, J. J., Song, P., Duan, J. L., & Wang, L. (2023). Oit3, a promising hallmark gene for targeting liver sinusoidal endothelial cells. Signal Transduction and Targeted Therapy, 8(1), 344.

Yang, S., Zhang, J., Xu, Y., Wang, J., Zhao, H., Lei, J., ... & Li, Y. (2022). OIT3 mediates macrophage polarization and facilitates hepatocellular carcinoma progression. Cancer Immunology, Immunotherapy, 71(11), 2677-2689.

Wen, J., Aili, A., Yan, Y. X., Lai, Y., Niu, S., He, S., ... & Li, J. (2022). OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis via regulating the arachidonic acid metabolism. Frontiers in Oncology, 12, 977348.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols